Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Proposed policy solutions for the worldwide rise in chronic diseases

26

Mar 2026

Proposed policy solutions for the worldwide rise in chronic diseases

Chronic diseases including cancer, diabetes, neurocognitive disorders and infertility are rising globally, with health-harming products such as fossil fuels, tobacco, ultra‑processed foods, toxic chemicals, plastics and alcohol being major contributors, say the authors of a new paper published in New England Journal of Medicine (NEJM). The authors include proposed solutions, including policy safeguards and a stronger research focus on the risks to health connected with corporate activity.

Microtubules unveiled as active enzyme regulators

26

Mar 2026

Microtubules unveiled as active enzyme regulators

Microtubules, the dynamic filaments that form the cell's internal scaffolding, have long been viewed as mere passive structural supports. But a new study reveals they play a far more active signaling role. The findings, published in Science Advances, demonstrate that microtubules are in fact regulators of enzymatic reactions through reshaping the geometry of the enzyme's substrate proteins attached to them and controlling when key events occur to conduct cell division.

Scientists discover how brain development programs fuel pediatric tumors

26

Mar 2026

Scientists discover how brain development programs fuel pediatric tumors

A team of researchers at Baylor College of Medicine, St. Jude Children's Research Hospital, Texas Children's Hospital, and collaborating institutions reveals in the journal Nature a novel mechanism that drives the development of pediatric supratentorial ependymoma (EPN), the third most common pediatric brain tumor. The findings suggest potential new approaches to treat these aggressive and chemo-resistant tumors.

DICP scientists develop high-efficiency CO2 hydrogenation catalyst

26

Mar 2026

DICP scientists develop high-efficiency CO2 hydrogenation catalyst

Formate is a key chemical building block widely used across industries. Converting carbon dioxide (CO2) into formate via hydrogenation provides a promising approach to transform a greenhouse gas into a high-value chemical. However, while heterogeneous catalysts based on non-precious metals have been explored for this reaction, their practical application has been limited by low intrinsic reactivity.

Analyzing the disparity between youth and adult HPV uptake

26

Mar 2026

Analyzing the disparity between youth and adult HPV uptake

Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide and can cause various types of cancer. Prophylactic HPV vaccination is highly effective and has been recommended in Switzerland since 2007 for girls and young women aged 11 to 26 – and since 2015 also for boys and young men. Catch-up vaccination is also available for women up to the age of 45.

Study links androgens to aggressive childhood brain tumor growth

25

Mar 2026

Study links androgens to aggressive childhood brain tumor growth

An international team led by researchers at Baylor College of Medicine, Texas Children's Hospital, McGill University and University of Pittsburgh School of Medicine has discovered what drives the growth of a lethal pediatric brain tumor called Posterior Fossa Type A (PFA) ependymoma.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.